

ISSUE @ A GLANCE



TAVI is on the move! Results in low-risk patients, those with mitral disease, and those with cerebral protection

T.F. Lüscher

1309

CardioPulse

E. Blackburn, C. Greider, and J. Szostak: Chromosomes

M. Nicholls

1313

Alfred Nobel founder of Nobel Prize

M. Nicholls

1315

John Ormiston MBChB, FRCP, FACC

A. Davies

1317

EuroPCR 2017 Ethica Award

A. Tofield

1319

Leonard Kritharides MBBS PhD

J. Ozkan

1320

Mark Webster MBChB, MD, FRACEP

J. Ozkan

1321

FAST TRACK CLINICAL RESEARCH

TAVI

Patients at low surgical risk as defined by the Society of Thoracic Surgeons Score undergoing isolated interventional or surgical aortic valve implantation: in-hospital data and 1-year results from the German Aortic Valve Registry (GARY)

R. Bekeredjian, G. Szabo, Ü. Balaban, S. Bleiziffer, T. Bauer, S. Ensminger, C. Frerker, E. Herrmann, F. Beyersdorf, C. Hamm, A. Beckmann, H. Möllmann, M. Karck, H.A. Katus, and T. Walther


1323

Editorial

Transcatheter aortic valve implantation in patients with longer life expectancy: what measures are needed?

L. Sondergaard

1331



Rate of peri-procedural stroke observed with cerebral embolic protection during transcatheter aortic valve replacement: a patient-level propensity-matched analysis

J. Seeger, S.R. Kapadia, S. Kodali, A. Linke, J. Wöhrle, S. Haussig, R. Makkar, R. Mehran, W. Rottbauer, and M. Leon

1334

Editorial

Cerebral embolic protection during TAVI: prevent the unpreventable?

M. Abdel-Wahab and H. Thiele

1340



CLINICAL RESEARCH

TAVI

Transcatheter aortic valve replacement in patients with concomitant mitral stenosis

M. Asami, S. Windecker, F. Praz, J. Lanz, L. Hunziker, M. Rothenbühler, L. Räber, E. Roost, S. Stortecky, and T. Pilgrim

1342


Editorial

Concomitant mitral stenosis may be associated with low flow: what it means and how it potentially impacts on transcatheter aortic valve replacement

T. Bartel and S. Müller

1352

Valvular heart disease



Incidence of infective endocarditis in patients considered at moderate risk

L. Østergaard, N. Valeur, A. Wang, H. Bundgaard, M. Aslam, G. Gislason, C. Torp-Pedersen, N.E. Bruun, L. Søndergaard, L. Køber, and E.L. Fosbøl

1355

BASIC SCIENCE

Valvular heart disease

Activated platelets promote an osteogenic programme and the progression of calcific aortic valve stenosis

R. Bouchareb, M.-C. Boulanger, L. Tastet, G. Mkannez, M.J. Nsaibia, F. Hadji, A. Dahou, Y. Messadeq, B.J. Arsenaault, P. Pibarot, Y. Bossé, A. Murette, and P. Mathieu

1362

Editorial

Is there a role for activated platelets in progression of aortic valve calcification?

A. Sakamoto, L. Guo, R. Virmani, and A.V. Finn

1374

CURRENT OPINION

Prevention and epidemiology

Limitations of hazard ratios in clinical trials

M.J. Stensrud, J.M. Aalen, O.O. Aalen, and M. Valberg

1378

CARDIOVASCULAR FLASHLIGHTS

Valve-in-valve-in-valve with the New Valve Technology allegra transcatheter heart valve system

M. Miura, M. Taramasso, S. Obeid, and F. Nietlispach

1354

Intentional transcatheter laceration of the coronary cusp to prevent left main stem obstruction during transcatheter aortic valve implantation: first European experience with the BASILICA technique in a native aortic valve

A.M. Kasel, J.M. Khan, A.B. Greenbaum, and J.M. Michel

1384

CORRIGENDUM/ERRATUM

Corrigendum to: Incidence of infective endocarditis in patients considered at moderate risk

1361

Erratum to: Limitations of hazard ratios in clinical trials

1383



For the podcast associated with this article, please visit <https://academic.oup.com/eurheartj/pages/Podcasts>



Visit EIJ's mobile site

<https://academic.oup.com/eurheartj>



www.eurheartj.org